VANCOUVER, British Columbia, Aug. 19, 2026 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX-V: RKV) (FSE: 7JO0), a biopharmaceutical company advancing innovative cancer therapies through AI-powered drug discovery, is pleased to announce the results of voting at its 2026 annual general meeting of shareholders held on August 18, 2026, in Toronto, Ontario (the "Meeting").
All five members of the Company's board of directors named as nominees in its management information circular dated July 14, 2026 (the "Circular") were elected as directors: Kim Oishi, Frank Holler, Dr. David Kideckel, Yevgeniy Meshcherekov and Dr. Petra Hamerlik.
In addition, at the Meeting, the shareholders of the Company: (i) approved the setting of the number of directors at five; (ii) approved the re-appointment of Davidson & Company LLP as the Company's auditor until the next annual general meeting of shareholders, at a remuneration to be fixed by the board of directors; and (iii) re-approved the Company's existing omnibus equity incentive plan as set out in the Circular.
In connection with the Meeting, Jeffrey Bacha retired from the Company's board of directors and did not stand for re-election. Mr. Bacha will continue to support Rakovina in an advisory capacity. Dr. Petra Hamerlik joins the board as a new director following her election at the Meeting.
"On behalf of the board and the entire Rakovina team, I want to thank Mr. Bacha for his years of service and his dedication to this Company," said Kim Oishi, Chief Executive Officer of Rakovina Therapeutics. "Mr. Bacha helped build Rakovina from the ground up and guided it through many of its most important milestones. We are fortunate that he will continue to lend his experience to us as an advisor. I would also like to welcome Dr. Hamerlik to the board. Her scientific depth in the DNA-damage response and in neuro-oncology will be a real asset as we advance our programs toward the clinic."
About Rakovina Therapeutics Inc.
Rakovina Therapeutics is a biopharmaceutical research company focused on the development of innovative cancer treatments. Their work is based on unique technologies for targeting the DNA-damage response powered by Artificial Intelligence (AI) using validated, proprietary platforms. By using AI, they can review and optimize drug candidates at a much greater pace than ever before.
The Company has established a pipeline of distinctive DNA-damage response inhibitors with the goal of advancing one or more drug candidates into human clinical trials in collaboration with pharmaceutical partners.
Further information may be found at www.rakovinatherapeutics.com.
No regulatory authority has approved or disapproved the content of this press release. Neither the TSX Venture Exchange nor its Regulatory Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this press release.
Notice Regarding Forward-Looking Statements
This press release may contain "forward-looking statements" regarding the Company and its respective business within the meaning of applicable Canadian securities laws, including, without limitations, statements regarding: the Company's objectives, goals, or future plans regarding its cancer treatments or proposed business plan and expected results of the Company's DDR platform. Forward-looking statements are necessarily based upon a number of estimates and assumptions that, while considered reasonable by management, are inherently subject to significant business, economic, and competitive uncertainties and contingencies. Often, but not always, forward-looking statements can be identified by the use of words such as "plans", "is expected", "expects", "scheduled", "intends", "contemplates", "anticipates", "believes", "proposes" or variations (including negative variations) of such words and phrases, or state that certain actions, events, or results "may", "could", "would", "might" or "will" be taken, occur or be achieved.
The forward-looking events and circumstances discussed in this press release may not occur by certain specified dates or at all and could differ materially as a result of known and unknown risk factors and uncertainties affecting the Company, including risks regarding the biopharmaceutical industry, economic factors, regulatory factors, the equity markets generally, and risks associated with growth and competition. Although the Company has attempted to identify important factors that could cause actual actions, events, or results to differ materially from those described in forward-looking statements, there may be other factors that cause actions, events, or results to differ from those anticipated, estimated, or intended. No forward-looking statement can be guaranteed. Except as required by applicable securities laws, forward-looking statements speak only as of the date on which they are made and the Company undertakes no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events, or otherwise.
The reader is referred to the Company's most recent filings on SEDAR+ for a more complete discussion of all applicable risk factors and their potential effects, copies of which may be accessed through the Company's profile page at www.sedarplus.ca.
For Further Information Contact:
Investor Relations
Rakovina Therapeutics Inc.
IR@rakovinatherapeutics.com
